What are the treatment options for non–small cell lung cancer (NSCLC) in patients with MET exon 14 skipping mutations?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with MET exon 14 skipping mutation, the following agents are used:

  • Capmatinib (Tabrecta) (preferred)
  • Tepotinib (Tepmetko) (preferred)
  • Crizotinib if the mutation is discovered during first-line systemic therapy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!